Histologic Evidence of Orbital Inflammation from Retrobulbar @entity285 and XXXX Injection: A Clinicopathologic Study in @entity1 _ @entity35 Orbits.

@entity1 @entity32 @entity2644 @entity158 @entity35 @entity3856 @entity285
PURPOSE: Retrobulbar injections of @entity285 and @entity2644 are used for the treatment of blind, @entity3856 . There have been reports of @entity32 after retrobulbar injections of these agents, but the histologic effects are not well characterized. A clinical case with histopathologic @entity32 after retrobulbar @entity285 injection led the authors to develop a @entity35 model to examine these effects. METHODS: Adult Lewis @entity35 were given retrobulbar injections of either 0.1 ml of absolute @entity285 or 25 mg/ml @entity2644 in the right orbit, and 0.1 ml of saline in the left orbit as a control. @entity35 were euthanized, perfused, and postfixed at 1 to 2 weeks after injection. Exenterated orbital tissue was sectioned for histologic staining. Slides were reviewed by a masked ocular pathologist who evaluated the level of orbital @entity32 . RESULTS: Histopathology demonstrated foci of @entity32 in the orbit of the @entity1 and similar @entity32 in the @entity35 orbits injected with retrobulbar @entity285 . In the @entity2644 group, only 1 @entity35 demonstrated small foci of @entity32 , while the control orbits injected with saline showed no @entity32 . On blinded qualitative analysis, the orbits receiving retrobulbar @entity285 had greater @entity32 than the orbits receiving either saline or @entity2644 . CONCLUSIONS: Our findings in this preclinical pilot study suggest that retrobulbar @entity285 injections @entity32 , whereas retrobulbar @entity2644 induces little or no @entity32 . This potential inflammatory response should be considered when selecting an agent for @entity158 management, particularly if future orbital surgery is anticipated.
